<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5728039</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0472</article-id><article-id pub-id-type="publisher-id">ONCO12293</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>6</subject><subject>31</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab&#8208;Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results</article-title></title-group><contrib-group><contrib id="onco12293-cr-0001" contrib-type="author" corresp="yes"><name><surname>O'Reilly</surname><given-names>Eileen M.</given-names></name><address><email>oreillye@mskcc.org</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12293-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12293-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12293-cr-0002" contrib-type="author"><name><surname>Roach</surname><given-names>James</given-names></name><xref ref-type="aff" rid="onco12293-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12293-cr-0003" contrib-type="author"><name><surname>Miller</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="onco12293-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12293-cr-0004" contrib-type="author"><name><surname>Yu</surname><given-names>Kenneth H.</given-names></name><xref ref-type="aff" rid="onco12293-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12293-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12293-cr-0005" contrib-type="author"><name><surname>Tjan</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="onco12293-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12293-cr-0006" contrib-type="author"><name><surname>Rosano</surname><given-names>Molly</given-names></name><xref ref-type="aff" rid="onco12293-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12293-cr-0007" contrib-type="author"><name><surname>Krause</surname><given-names>Silva</given-names></name><xref ref-type="aff" rid="onco12293-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12293-cr-0008" contrib-type="author"><name><surname>Avery</surname><given-names>William</given-names></name><xref ref-type="aff" rid="onco12293-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12293-cr-0009" contrib-type="author"><name><surname>Wolf</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="onco12293-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12293-cr-00010" contrib-type="author"><name><surname>Flaherty</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="onco12293-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12293-cr-00011" contrib-type="author"><name><surname>Nix</surname><given-names>Darrell</given-names></name><xref ref-type="aff" rid="onco12293-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12293-cr-00012" contrib-type="author"><name><surname>Ryan</surname><given-names>David P.</given-names></name><xref ref-type="aff" rid="onco12293-aff-0005"><sup>e</sup></xref></contrib><aff id="onco12293-aff-0001"><label><sup>a</sup></label>
<institution>Memorial Sloan Kettering Cancer Center, Department of Medicine</institution>, <city>New York</city>, <state>New York</state>, <country>USA</country>
</aff><aff id="onco12293-aff-0002"><label><sup>b</sup></label>
<institution>Weill Cornell Medical College, Department of Medicine</institution>, <city>New York</city>, <state>New York</state>, <country>USA</country>
</aff><aff id="onco12293-aff-0003"><label><sup>c</sup></label><institution>Momenta Pharmaceuticals</institution>, <city>Cambridge</city>, <state>Massachusetts</state>, <country>USA</country>
</aff><aff id="onco12293-aff-0004"><label><sup>d</sup></label><institution>Novella Clinical</institution>, <city>Morrisville</city>, <state>North Carolina</state>, <country>USA</country>
</aff><aff id="onco12293-aff-0005"><label><sup>e</sup></label>
<institution>Massachusetts General Hospital, Department of Medicine</institution>, <city>Boston</city>, <state>Massachusetts</state>, <country>USA</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Eileen M. O'Reilly, M.D., Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New YorK, NY 10065. Telephone: 646&#8208;888&#8208;4182; e&#8208;mail: <email>oreillye@mskcc.org</email></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>12</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/onco.v22.12</issue-id><fpage>1429</fpage><lpage>e139</lpage><history><date date-type="received"><day>20</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">&#169; AlphaMed Press; the data published online to support this summary is the property of the authors</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12293.pdf"/><abstract><title>Abstract</title><sec id="onco12293-sec-1001"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12293-list-0002"><list-item id="onco12293-li-0005"><p>Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.</p></list-item><list-item id="onco12293-li-0006"><p>Safety was documented, although dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity (cellulitis), and low&#8208;level anticoagulant effect. Nonetheless, the hypothesis of targeting prothrombotic pathways in pancreas adenocarcinoma remains compelling.</p></list-item></list></p></sec><sec id="onco12293-sec-0001"><title>Background.</title><p>Necuparanib is derived from unfractionated heparin and engineered for reduced anticoagulant activity while preserving known heparin&#8208;associated antitumor properties. This trial assessed the safety, pharmacokinetics (PK), pharmacodynamics, and initial efficacy of necuparanib combined with gemcitabine&#8201;&#177;&#8201;nab&#8208;paclitaxel in patients with metastatic pancreatic cancer.</p></sec><sec id="onco12293-sec-0002"><title>Methods.</title><p>Patients received escalating daily subcutaneous doses of necuparanib plus 1,000 mg/m<sup>2</sup> gemcitabine (days 1, 8, 15, and every 28 days). The protocol was amended to include 125 mg/m<sup>2</sup> nab&#8208;paclitaxel after two cohorts (following release of the phase III MPACT data). The necuparanib starting dose was 0.5 mg/kg, with escalation via a modified 3&#8201;+&#8201;3 design until the maximum tolerated dose (MTD) was determined.</p></sec><sec id="onco12293-sec-0003"><title>Results.</title><p>Thirty&#8208;nine patients were enrolled into seven cohorts (necuparanib 0.5, 1 mg/kg&#8201;+&#8201;gemcitabine; necuparanib 1, 2, 4, 6, and 5 mg/kg&#8201;+&#8201;nab&#8208;paclitaxel&#8201;+&#8201;gemcitabine). The most common adverse events were anemia (56%), fatigue (51%), neutropenia (51%), leukopenia (41%), and thrombocytopenia (41%). No deaths and two serious adverse events were potentially related to necuparanib. Measurable levels of necuparanib were seen starting at the 2 mg/kg dose. Of 24 patients who received at least one dose of necuparanib&#8201;+&#8201;nab&#8208;paclitaxel&#8201;+&#8201;gemcitabine, 9 (38%) achieved a partial response and 6 (25%) achieved stable disease (63% disease control rate). Given a cellulitis event and mild activated partial thromboplastin time increases at 6 mg/kg, the 5 mg/kg dose was considered the MTD and selected for further assessment in phase II.</p></sec><sec id="onco12293-sec-0004"><title>Conclusion.</title><p>Acceptable safety and encouraging signals of activity in patients with metastatic pancreatic cancer receiving necuparanib, nab&#8208;paclitaxel, and gemcitabine were demonstrated.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh"><bold>&#25688;&#35201;</bold></p><p xml:lang="zh"><bold><italic>&#32972;&#26223;</italic>.</bold>Necuparanib&#26159;&#26222;&#36890;&#32925;&#32032;&#30340;&#34893;&#29983;&#29289;, &#32463;&#22522;&#22240;&#25913;&#36896;&#20026;&#22312;&#20445;&#30041;&#24050;&#30693;&#32925;&#32032;&#30456;&#20851;&#25239;&#32959;&#30244;&#29305;&#24615;&#30340;&#21516;&#26102;&#38477;&#20302;&#25239;&#20957;&#34880;&#27963;&#24615;&#12290;&#26412;&#35797;&#39564;&#35780;&#20272;&#20102;necuparanib&#32852;&#21512;&#21513;&#35199;&#20182;&#28392;&#177;&#30333;&#34507;&#30333;&#32467;&#21512;&#22411;&#32043;&#26441;&#37255;&#27835;&#30103;&#36716;&#31227;&#24615;&#33008;&#33146;&#30284;&#24739;&#32773;&#30340;&#23433;&#20840;&#24615;&#12289;&#33647;&#20195;&#21160;&#21147;&#23398;&#65288;PK&#65289;&#12289;&#33647;&#25928;&#23398;&#21644;&#21021;&#22987;&#30103;&#25928;&#12290;</p><p xml:lang="zh"><bold><italic>&#26448;&#26009;&#19982;&#26041;&#27861;</italic>.</bold>&#24739;&#32773;&#27599;&#22825;&#25509;&#21463;&#21058;&#37327;&#36882;&#22686;&#30340;necuparanib&#30382;&#19979;&#27880;&#23556;+&#21513;&#35199;&#20182;&#28392;1,000 mg/m<sup>2</sup>&#65288;&#31532;1&#12289;8&#21644;15&#22825;, 28&#22825;&#19968;&#20010;&#21608;&#26399;&#65289;&#12290;&#22312;&#20004;&#20010;&#38431;&#21015;&#21518;&#23545;&#26041;&#26696;&#36827;&#34892;&#20102;&#20462;&#35746;, &#32435;&#20837;&#30333;&#34507;&#30333;&#32467;&#21512;&#22411;&#32043;&#26441;&#37255;125 mg/m<sup>2</sup>&#65288;&#21457;&#24067;III&#26399;MPACT&#25968;&#25454;&#20043;&#21518;&#65289;&#12290;Necuparanib&#30340;&#36215;&#22987;&#21058;&#37327;&#20026;0.5mg/kg, &#36890;&#36807;&#20462;&#35746;&#21518;&#30340;3&#8201;+&#8201;3&#35774;&#35745;&#36827;&#34892;&#21058;&#37327;&#36882;&#22686;, &#30452;&#33267;&#30830;&#23450;&#26368;&#22823;&#32784;&#21463;&#21058;&#37327;&#65288;MTD&#65289;&#12290;</p><p xml:lang="zh"><bold><italic>&#32467;&#26524;</italic>.</bold>39&#20363;&#24739;&#32773;&#20837;&#32452;&#36827;&#20837;7&#20010;&#38431;&#21015;&#65288;necuparanib 0.5, 1 mg/kg +&#21513;&#35199;&#20182;&#28392;&#65307;necuparanib 1, 2, 4, 6&#21644;5 mg/kg +&#30333;&#34507;&#30333;&#32467;&#21512;&#22411;&#32043;&#26441;&#37255;+&#21513;&#35199;&#20182;&#28392;&#65289;&#12290;&#26368;&#24120;&#35265;&#30340;&#19981;&#33391;&#20107;&#20214;&#20026;&#36139;&#34880;&#65288;56%&#65289;&#12289;&#30130;&#20047;&#65288;51%&#65289;&#12289;&#20013;&#24615;&#31890;&#32454;&#32990;&#20943;&#23569;&#30151;&#65288;51%&#65289;&#12289;&#30333;&#32454;&#32990;&#20943;&#23569;&#30151;&#65288;41%&#65289;&#21644;&#34880;&#23567;&#26495;&#20943;&#23569;&#30151;&#65288;41%&#65289;&#12290;&#30740;&#31350;&#26399;&#38388;&#21457;&#29983;&#20102;&#20004;&#36215;&#21487;&#33021;&#19982;necuparanib&#26377;&#20851;&#30340;&#20005;&#37325;&#19981;&#33391;&#20107;&#20214;, &#26410;&#21457;&#29983;&#27515;&#20129;&#20107;&#20214;&#12290;&#20174;2 mg/kg&#21058;&#37327;&#27700;&#24179;&#24320;&#22987;&#21487;&#26816;&#20986;necuparanib&#12290;&#22312;&#33267;&#23569;&#25509;&#21463;&#20102;1&#27425;necuparanib+&#30333;&#34507;&#30333;&#32467;&#21512;&#22411;&#32043;&#26441;&#37255;+&#21513;&#35199;&#20182;&#28392;&#32473;&#33647;&#30340;24&#20363;&#24739;&#32773;&#20013;, 9&#20363;&#65288;38%&#65289;&#24739;&#32773;&#36798;&#21040;&#37096;&#20998;&#32531;&#35299;, 6&#20363;&#65288;25%&#65289;&#36798;&#21040;&#30142;&#30149;&#31283;&#23450;&#65288;63%&#30142;&#30149;&#25511;&#21046;&#29575;&#65289;&#12290;&#30001;&#20110;6 mg/kg&#21058;&#37327;&#27700;&#24179;&#19979;&#21457;&#29983;&#34562;&#31389;&#32455;&#28814;&#20107;&#20214;&#21644;&#27963;&#21270;&#37096;&#20998;&#20957;&#34880;&#27963;&#37238;&#26102;&#38388;&#36731;&#24230;&#24310;&#38271;, &#21028;&#23450;5 mg/kg&#21058;&#37327;&#27700;&#24179;&#20026;MTD&#24182;&#19988;&#23558;&#22312;II&#26399;&#30740;&#31350;&#20013;&#23545;&#20854;&#36827;&#34892;&#36827;&#19968;&#27493;&#35780;&#20272;&#12290;</p><p xml:lang="zh"><bold><italic>&#32467;&#35770;</italic>.</bold>&#30740;&#31350;&#35777;&#23454;&#25509;&#21463;necuparanib&#12289;&#30333;&#34507;&#30333;&#32467;&#21512;&#22411;&#32043;&#26441;&#37255;&#21644;&#21513;&#35199;&#20182;&#28392;&#27835;&#30103;&#30340;&#36716;&#31227;&#24615;&#33008;&#33146;&#30284;&#24739;&#32773;&#30340;&#23433;&#20840;&#24615;&#21487;&#25509;&#21463;&#19988;&#27963;&#24615;&#36739;&#22909;&#12290;</p></trans-abstract><counts><page-count count="12"/></counts></article-meta></front><body><sec sec-type="discussion" id="onco12293-sec-0005"><title>Discussion</title><p>Heparins are present as cell surface glycosaminoglycans and have crucial regulatory roles in normal physiological processes and pathophysiological conditions, including tumor onset, proliferation, and metastasis [<xref rid="onco12293-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12293-bib-0002" ref-type="ref">2</xref>], [<xref rid="onco12293-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12293-bib-0004" ref-type="ref">4</xref>]. Possible antitumor effects of heparin include prevention of metastasis via inhibition of heparanase and interaction with P&#8208;selectin [<xref rid="onco12293-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12293-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12293-bib-0007" ref-type="ref">7</xref>], [<xref rid="onco12293-bib-0008" ref-type="ref">8</xref>], [<xref rid="onco12293-bib-0009" ref-type="ref">9</xref>], [<xref rid="onco12293-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12293-bib-0011" ref-type="ref">11</xref>], [<xref rid="onco12293-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12293-bib-0013" ref-type="ref">13</xref>], [<xref rid="onco12293-bib-0014" ref-type="ref">14</xref>]. Heparin administration is limited by its anticoagulant effects. Necuparanib is a noncytotoxic, glycol&#8208;split, heparan sulfate mimetic intended to treat advanced malignancies. Necuparanib is rationally engineered from heparin through a process that reduces anticoagulant activity while preserving activity against a number of heparin&#8208;binding proteins involved in tumor progression and metastasis. [<xref rid="onco12293-bib-0015" ref-type="ref">15</xref>], [<xref rid="onco12293-bib-0016" ref-type="ref">16</xref>], [<xref rid="onco12293-bib-0017" ref-type="ref">17</xref>]</p></sec><sec id="onco12293-sec-9905"><p><table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p><p>
<table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-3" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0002"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12293-sec-8905"><p>This is the first clinical evaluation of necuparanib, a novel therapeutic agent, which was conducted in patients with metastatic pancreatic adenocarcinoma. Necuparanib in combination with nab&#8208;paclitaxel and gemcitabine demonstrated acceptable tolerability. No clear dose&#8208;proportional trends in individual adverse events (AEs) were observed. The most common AEs had comparable rates, when necuparanib was administered with gemcitabine with or without nab&#8208;paclitaxel, to what would be expected with chemotherapy alone. The grade 3/4 hematological toxicities observed in this study in the necuparanib&#8201;+&#8201;nab&#8208;paclitaxel and gemcitabine cohort were similar to those observed in the Von Hoff phase III MPACT trial (neutropenia, 3% vs. 38%; anemia, 3% vs. 13%; and thrombocytopenia, 0% vs. 13%, respectively). No grade 3/4 AEs of leukocytosis, febrile neutropenia, epistaxis, pulmonary embolism, deep vein thrombosis, phlebitis, or hematuria were reported with the necuparanib&#8201;+&#8201;nab&#8208;paclitaxel and gemcitabine regimen.</p><p>Based on collective safety and on PK, progressive disease (PD), biomarker, and efficacy data, a 5 mg/kg necuparanib dose, with capping at 450 mg, providing for a reasonable injection volume (i.e., two injections daily), was selected for further clinical evaluation in part B (randomized phase II trial). Pharmacodynamic data (i.e., hepatocyte growth factor) showed saturation with necuparanib 5 mg/kg and subtherapeutic levels of anticoagulation, which may be beneficial for thrombosis prevention. Promising antitumor activity was observed, as evidenced by survival and response data, with an overall disease&#8208;control rate of 63% when all dose cohorts were pooled. Similarly, promising effects on reduction in Carbohydrate antigen 19&#8208;9 (CA19.9) levels from baseline with necuparanib treatment were observed. The median overall survival for patients who received at least one dose (13.1 months) and at least one cycle (15.6 months) of necuparanib&#8201;+&#8201;nab<italic>&#8208;</italic>paclitaxel&#8201;+&#8201;gemcitabine compared favorably with the phase III data for nab<italic>&#8208;</italic>paclitaxel&#8201;+&#8201;gemcitabine (8.5 months), differences in sample sizes and study populations notwithstanding [<xref rid="onco12293-bib-0018" ref-type="ref">18</xref>].</p><p>These encouraging phase I results supported further clinical investigation in part B of this two&#8208;part study; however, the phase II portion of the trial was discontinued following a planned interim futility analysis, which did not show a sufficient level of efficacy to warrant continuation of study accrual. The phase II results will be reported separately.</p></sec><sec id="onco12293-sec-0006"><title>Trial Information</title><p>
<def-list id="onco12293-lp-0001"><def-item><term id="onco12293-li-0007">Disease</term><def id="onco12293-li-0008"><p>Pancreatic cancer</p></def></def-item><def-item><term id="onco12293-li-0009">Stage of Disease/Treatment</term><def id="onco12293-li-0010"><p>Metastatic/advanced</p></def></def-item><def-item><term id="onco12293-li-0011">Prior Therapy</term><def id="onco12293-li-0012"><p>None</p></def></def-item><def-item><term id="onco12293-li-0013">Type of Study &#8211; 1</term><def id="onco12293-li-0014"><p>Phase I</p></def></def-item><def-item><term id="onco12293-li-0015">Type of Study &#8211; 2</term><def id="onco12293-li-0016"><p>3&#8201;+&#8201;3</p></def></def-item><def-item><term id="onco12293-li-0017">Primary Endpoint</term><def id="onco12293-li-0018"><p>Safety</p></def></def-item><def-item><term id="onco12293-li-0019">Primary Endpoint</term><def id="onco12293-li-0020"><p>Tolerability</p></def></def-item><def-item><term id="onco12293-li-0021">Secondary Endpoin</term><def id="onco12293-li-0022"><p>MTD</p></def></def-item><def-item><term id="onco12293-li-0023">Secondary Endpoint</term><def id="onco12293-li-0024"><p>Recommended phase II dose</p></def></def-item><def-item><term id="onco12293-li-0025">Secondary Endpoint</term><def id="onco12293-li-0026"><p>PK</p></def></def-item><def-item><term id="onco12293-li-0027">Secondary Endpoint</term><def id="onco12293-li-0028"><p>PD</p></def></def-item><def-item><term id="onco12293-li-0029"><bold>Additional Details of Endpoints or Study Design</bold> This was a phase I, open&#8208;label, multiple ascending&#8208;dose study of necuparanib given as monotherapy and then in combination with nab<italic>&#8208;</italic>paclitaxel and gemcitabine for patients with newly diagnosed untreated metastatic pancreas adenocarcinoma. Following completion of the first two cohorts (0.5 and 1.0 mg/kg necuparanib&#8201;+&#8201;gemcitabine), a protocol amendment in 2013 added nab&#8208;paclitaxel to the regimen following the presentation of MPACT study results supporting the combination. Dose escalation was conducted via a modified 3&#8201;+&#8201;3 design and occurred if all patients in the studied cohort completed cycle 1 without a dose&#8208;limiting toxicity (DLT). If a DLT was observed in one patient in the initial cohort of three to four patients, the cohort was expanded to six or seven patients. Dose escalation continued until the maximum tolerated dose (MTD) was defined. The protocol was modified during cohort 6 dosing to specify a maximum necuparanib dose of 450 mg (maximum of two injections of 225 mg/1.5 mL for each injection) following indications that daily doses greater than this were associated with elevated coagulation parameters. Dose escalation was to be terminated if two patients in the same cohort experienced a DLT in cycle 1. A DLT was defined as any AE judged by the investigator to be drug&#8208;related and assessed as grade &#8805;3 according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Safety data in patients who received at least one dose of at least one of the study drugs were summarized by treatment group, and descriptive statistics were calculated for quantitative data and differences from baseline, as appropriate. Pharmacokinetic and PD parameters were calculated using noncompartmental methods and summarized by treatment group using descriptive statistics.</term><def id="onco12293-li-0030"><p>&#160;</p></def></def-item><def-item><term id="onco12293-li-0037">Investigator's Analysis</term><def id="onco12293-li-0038"><p>Activity and safety demonstrated. Proceeded to randomized phase II, but futility met in phase II</p></def></def-item></def-list></p></sec><sec id="onco12293-sec-0007"><title>Drug Information for Phase I Control</title><p>
<def-list id="onco12293-lp-0002"><def-item><term id="onco12293-li-0039">Drug 1</term><def id="onco12293-li-0040"><p>&#160;</p></def></def-item><def-item><term id="onco12293-li-0041">Generic/Working name</term><def id="onco12293-li-0042"><p>Necuparanib</p></def></def-item><def-item><term id="onco12293-li-0043">Company name</term><def id="onco12293-li-0044"><p>Momenta Pharmaceuticals</p></def></def-item><def-item><term id="onco12293-li-0045">Drug type</term><def id="onco12293-li-0046"><p>Biological</p></def></def-item><def-item><term id="onco12293-li-0047">Drug class</term><def id="onco12293-li-0048"><p>Other: heparan sulfate mimetic</p></def></def-item><def-item><term id="onco12293-li-0049">Dose</term><def id="onco12293-li-0050"><p>0.5&#8211;5 milligrams (mg) per kilogram (kg)</p></def></def-item><def-item><term id="onco12293-li-0051">Route</term><def id="onco12293-li-0052"><p>Other: subcutaneous</p></def></def-item><def-item><term id="onco12293-li-0053">Schedule of administration</term><def id="onco12293-li-0054"><p>Daily subcutaneous doses in cohorts from 0.5 to 5 mg/kg; dose capped at 450 mg</p></def></def-item><def-item><term id="onco12293-li-0055">Drug 2</term><def id="onco12293-li-0056"><p>&#160;</p></def></def-item><def-item><term id="onco12293-li-0057">Generic/Working name</term><def id="onco12293-li-0058"><p>Nab&#8208;paclitaxel</p></def></def-item><def-item><term id="onco12293-li-0059">Trade name</term><def id="onco12293-li-0060"><p>Abraxane</p></def></def-item><def-item><term id="onco12293-li-0061">Company name</term><def id="onco12293-li-0062"><p>Celgene</p></def></def-item><def-item><term id="onco12293-li-0063">Drug type</term><def id="onco12293-li-0064"><p>Small molecule</p></def></def-item><def-item><term id="onco12293-li-0065">Drug class</term><def id="onco12293-li-0066"><p>Tubulin/Microtubules targeting agent</p></def></def-item><def-item><term id="onco12293-li-0067">Dose</term><def id="onco12293-li-0068"><p>125 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12293-li-0069">Route</term><def id="onco12293-li-0070"><p>IV</p></def></def-item><def-item><term id="onco12293-li-0071">Schedule of administration</term><def id="onco12293-li-0072"><p>Days 1, 8, and 15 of a 28&#8208;day cycle</p></def></def-item><def-item><term id="onco12293-li-0073">Drug 3</term><def id="onco12293-li-0074"><p>&#160;</p></def></def-item><def-item><term id="onco12293-li-0075">Generic/Working name</term><def id="onco12293-li-0076"><p>Gemcitabine</p></def></def-item><def-item><term id="onco12293-li-0077">Trade name</term><def id="onco12293-li-0078"><p>Gemzar</p></def></def-item><def-item><term id="onco12293-li-0079">Company name</term><def id="onco12293-li-0080"><p>Eli Lilly</p></def></def-item><def-item><term id="onco12293-li-0081">Drug type</term><def id="onco12293-li-0082"><p>Small molecule</p></def></def-item><def-item><term id="onco12293-li-0083">Drug class</term><def id="onco12293-li-0084"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12293-li-0085">Dose</term><def id="onco12293-li-0086"><p>1,000 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12293-li-0087">Route</term><def id="onco12293-li-0088"><p>IV</p></def></def-item><def-item><term id="onco12293-li-0089">Schedule of administration</term><def id="onco12293-li-0090"><p>Days 1, 8, and 15 of a 28&#8208;day cycle</p></def></def-item><def-item><term id="onco12293-li-0091">Drug 4</term><def id="onco12293-li-0092"><p>&#160;</p></def></def-item><def-item><term id="onco12293-li-0093">Generic/Working name</term><def id="onco12293-li-0094"><p>New drug</p></def></def-item><def-item><term id="onco12293-li-0095">Company name</term><def id="onco12293-li-0096"><p>Momenta Pharmaceuticals</p></def></def-item><def-item><term id="onco12293-li-0097">Drug type</term><def id="onco12293-li-0098"><p>Biological</p></def></def-item><def-item><term id="onco12293-li-0099">Drug class</term><def id="onco12293-li-0100"><p>Other</p></def></def-item><def-item><term id="onco12293-li-0101">Dose</term><def id="onco12293-li-0102"><p>0.5 mg/kg</p></def></def-item><def-item><term id="onco12293-li-0103">Route</term><def id="onco12293-li-0104"><p>Subcutaneous</p></def></def-item></def-list></p></sec><sec id="onco12293-sec-0008"><title>Patient Characteristics for Phase I Control</title><p>
<def-list id="onco12293-lp-0003"><def-item><term id="onco12293-li-0105">Number of Patients, Male</term><def id="onco12293-li-0106"><p>12</p></def></def-item><def-item><term id="onco12293-li-0107">Number of Patients, Female</term><def id="onco12293-li-0108"><p>27</p></def></def-item><def-item><term id="onco12293-li-0109">Stage</term><def id="onco12293-li-0110"><p>IV pancreas adenocarcinoma</p></def></def-item><def-item><term id="onco12293-li-0111">Age</term><def id="onco12293-li-0112"><p>Median (range): 63 years</p></def></def-item><def-item><term id="onco12293-li-0113">Number of Prior Systemic Therapies</term><def id="onco12293-li-0114"><p>Median (range): 0</p></def></def-item><def-item><term id="onco12293-li-0115">Performance Status: ECOG</term><def id="onco12293-li-0116"><p>0 &#8212; 21</p><p>1 &#8212; 18</p><p>2 &#8212;</p><p>3 &#8212;</p><p>Unknown &#8212;</p></def></def-item></def-list>
</p></sec><sec id="onco12293-sec-0009"><title>Primary Assessment Method for Phase I Control</title><p>
<def-list id="onco12293-lp-0004"><def-item><term id="onco12293-li-0125">Title</term><def id="onco12293-li-0126"><p>Necuparanib, nab&#8208;paclitaxel, gemcitabine (<italic>n</italic>&#8201;=&#8201;24)</p></def></def-item><def-item><term id="onco12293-li-0127">Number of Patients Enrolled</term><def id="onco12293-li-0128"><p>39</p></def></def-item><def-item><term id="onco12293-li-0129">Number of Patients Evaluable for Toxicity</term><def id="onco12293-li-0130"><p>39</p></def></def-item><def-item><term id="onco12293-li-0131">Number of Patients Evaluated for Efficacy</term><def id="onco12293-li-0132"><p>24</p></def></def-item><def-item><term id="onco12293-li-0133">Evaluation Method</term><def id="onco12293-li-0134"><p>RECIST 1.1</p></def></def-item><def-item><term id="onco12293-li-0135">Response Assessment CR</term><def id="onco12293-li-0136"><p><italic>n</italic>&#8201;=&#8201;0 (0%)</p></def></def-item><def-item><term id="onco12293-li-0137">Response Assessment PR</term><def id="onco12293-li-0138"><p><italic>n</italic>&#8201;=&#8201;9 (38%)</p></def></def-item><def-item><term id="onco12293-li-0139">Response Assessment SD</term><def id="onco12293-li-0140"><p><italic>n</italic>&#8201;=&#8201;6 (25%)</p></def></def-item><def-item><term id="onco12293-li-0141">Response Assessment PD</term><def id="onco12293-li-0142"><p><italic>n</italic>&#8201;=&#8201;2 (8%)</p></def></def-item><def-item><term id="onco12293-li-0143">(Median) Duration Assessments PFS</term><def id="onco12293-li-0144"><p>5.9 months, CI: 2.1&#8211;8.7</p></def></def-item><def-item><term id="onco12293-li-0145">(Median) Duration Assessments OS</term><def id="onco12293-li-0146"><p>13.1 months, CI: 4.0&#8211;16.6</p></def></def-item></def-list></p></sec><sec id="onco12293-sec-0010"><title>Phase I Control Adverse Events</title><p>
<table-wrap id="nlm-table-wrap-3" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0003"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12293-note-0003"><p><italic>n</italic> (%) patients are shown. Adverse events have been sorted by necuparanib&#8201;+&#8201;gemcitabine&#8201;+&#8201;nab&#8208;paclitaxel (cohort 3&#8211;7 total) results.</p></fn><fn id="onco12293-note-0004"><p>Abbreviations: &#8212;, no adverse event; &#8593;, increased; AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co, cohort.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="onco12293-sec-0011"><title>Dose&#8208;Limiting Toxicities Table</title><p>
<table-wrap id="nlm-table-wrap-4" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0004"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12293-note-1007"><p>Abbreviations: aPTT, activated partial thromboplastin time; LFT, liver function test.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="onco12293-sec-0012"><title>Assessment, Analysis, and Discussion</title><p>
<def-list id="onco12293-lp-0005"><def-item><term id="onco12293-li-0147">Completion</term><def id="onco12293-li-0148"><p>Study completed</p></def></def-item><def-item><term id="onco12293-li-0149">Investigator's Assessment</term><def id="onco12293-li-0150"><p>Activity and safety demonstrated. Proceeded to randomized phase II, but futility met in phase II</p></def></def-item></def-list></p></sec><sec id="onco12293-sec-0013"><p>This was the first clinical evaluation of necuparanib, a novel therapeutic agent, which was conducted in patients with metastatic pancreatic adenocarcinoma. Necuparanib in combination with nab&#8208;paclitaxel and gemcitabine demonstrated acceptable tolerability. No clear dose&#8208;proportional trends in individual adverse events (AEs) were observed. The most common AEs had comparable rates, when necuparanib was administered with gemcitabine with or without nab&#8208;paclitaxel, to what would be expected with chemotherapy alone. With the exception of anemia, the grade 3/4 hematological toxicities observed in this study in the necuparanib&#8201;+&#8201;nab&#8208;paclitaxel and gemcitabine cohort were similar to those observed in the Von Hoff et al. phase III study (neutropenia, 3% vs. 38%; anemia, 3% vs. 13%; and thrombocytopenia, 0% vs. 13%, respectively). No grade 3/4 AEs of leukocytosis, febrile neutropenia, epistaxis, pulmonary embolism, deep vein thrombosis, phlebitis, or hematuria were reported with the necuparanib&#8201;+&#8201;nab&#8208;paclitaxel and gemcitabine regimen.</p><p>Based on collective safety and on pharmacokinetic, progressive disease, biomarker, and efficacy data, a 5 mg/kg necuparanib dose, with capping at 450 mg, providing for a reasonable injection volume (i.e., two injections daily), was selected for further clinical evaluation in part B. Progressive disease data (i.e., hepatocyte growth factor) showed saturation with necuparanib 5 mg/kg and subtherapeutic levels of anticoagulation, which may be beneficial for thrombosis prevention. Promising antitumor activity was observed, as evidenced by survival and response data, with an overall disease&#8208;control rate of 63% when all dose cohorts were pooled. Similarly, promising effects on reduction in CA19.9 levels from baseline with necuparanib treatment were observed. The median OS for patients who received at least one dose (13.1 months) and at least one cycle (15.6 months) of necuparanib&#8201;+&#8201;nab<italic>&#8208;</italic>paclitaxel&#8201;+&#8201;gemcitabine compared favorably with the phase III data for nab<italic>&#8208;</italic>paclitaxel&#8201;+&#8201;gemcitabine (8.5 months), differences in sample sizes and study populations notwithstanding.</p><p>These encouraging phase I results supported further clinical investigation in part B of this two&#8208;part study; however, the phase II portion of the trial was discontinued following a planned interim futility analysis, which did not show a sufficient level of efficacy to warrant continuation of study accrual. The phase II results will be documented in a separate publication.</p></sec><sec id="onco12293-sec-1017"><title>Figures and Tables</title><fig fig-type="Figure" xml:lang="en" id="onco12293-fig-0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Dose escalation and disposition in patients receiving at least one dose of necuparanib.</p><p>Abbreviations: aPTT, activated partial thromboplastin time; DLT, dose&#8208;limiting toxicity; Gem, gemcitabine; HGF, hepatocyte growth factor; LFTs, liver function tests; NabP, nab&#8208;paclitaxel; Necu, necuparanib; PK, pharmacokinetics.</p></caption><graphic id="nlm-graphic-9" specific-use="sourcefile-name" xlink:href="onco12293-fig-0001"><alt-text>image</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="onco12293-fig-0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Concentration of necuparanib for patients with at least three measurable levels on day 1.</p></caption><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12293-fig-0002"><alt-text>image</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="onco12293-fig-0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Activated partial thromboplastin time and prothrombin time in patients who received necuparanib in combination with nab&#8208;paclitaxel and gemcitabine (cohorts 3&#8211;7).</p><p>Abbreviations: aPTT, activated partial thromboplastin time; PT, prothrombin time.</p></caption><graphic id="nlm-graphic-17" specific-use="sourcefile-name" xlink:href="onco12293-fig-0003"><alt-text>image</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="onco12293-fig-0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Mean (standard deviation) serum hepatocyte growth factor levels by dose group</p><p>Abbreviations: Gem, gemcitabine; HGF, hepatocyte growth factor; NabP, nab&#8208;paclitaxel; necu, necuparanib.</p></caption><graphic id="nlm-graphic-21" specific-use="sourcefile-name" xlink:href="onco12293-fig-0004"><alt-text>image</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="onco12293-fig-0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Patient time on study for patients receiving necuparanib&#8201;+&#8201;gemcitabine (cohorts 1 and 2; <bold>A</bold>) or necuparanib&#8201;+&#8201;nab&#8208;paclitaxel&#8201;+&#8201;gemcitabine (cohorts 3&#8211;7; <bold>B</bold>).</p><p>Abbreviations: Gem, gemcitabine; NabP, nab&#8208;paclitaxel; NE, not evaluable; Necu, necuparanib; PD, progressive disease; PR, partial response; SD, stable disease.</p></caption><graphic id="nlm-graphic-25" specific-use="sourcefile-name" xlink:href="onco12293-fig-0005"><alt-text>image</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="onco12293-fig-0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Patient time on study for patients receiving necuparanib&#8201;+&#8201;gemcitabine (cohorts 1 and 2; <bold>A</bold>) or necuparanib&#8201;+&#8201;nab&#8208;paclitaxel&#8201;+&#8201;gemcitabine (cohorts 3&#8211;7; <bold>B</bold>).</p><p>Abbreviations: Gem, gemcitabine; NabP, nab&#8208;paclitaxel; NE, not evaluable; Necu, necuparanib; PD, progressive disease; PR, partial response; SD, stable disease.</p></caption><graphic id="nlm-graphic-29" specific-use="sourcefile-name" xlink:href="onco12293-fig-0006"><alt-text>image</alt-text></graphic></fig><table-wrap id="onco12293-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Baseline patient and disease characteristics</title></caption><graphic id="nlm-graphic-33" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0005"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12293-note-0005"><p>Data were available for the following numbers of patients (necuparanib&#8201;+&#8201;gemcitabine, necuparanib&#8201;+&#8201;nab&#8208;paclitaxel&#8201;+&#8201;gemcitabine): ECOG (11, 24); tumor location and number of metastatic sites (12, 23); CA19.9 (9, 27).</p></fn><fn id="onco12293-note-0006"><p><sup>a</sup>Not available for three patients.</p></fn><fn id="onco12293-note-0007"><p>Abbreviations: BMI, body mass index; CA, cancer antigen; ECOG, Eastern Cooperative Oncology Group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="onco12293-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Summary of adverse events</title></caption><graphic id="nlm-graphic-35" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0006"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12293-note-0008"><p><italic>n</italic> (%) patients are shown. Adverse events have been sorted by necuparanib&#8201;+&#8201;gemcitabine&#8201;+&#8201;nab&#8208;paclitaxel (cohort 3&#8211;7 total) results.</p></fn><fn id="onco12293-note-0009"><p>Abbreviations: &#8212;, no adverse event; &#8593;, increased; AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co, cohort;</p></fn></table-wrap-foot></table-wrap><table-wrap id="onco12293-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Efficacy outcomes</title></caption><graphic id="nlm-graphic-37" specific-use="sourcefile-name" xlink:href="onco12293-tbl-0007"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12293-note-0010"><p>Abbreviations: CI, confidence interval; CR, complete response; mo, Month; NE, not evaluable; PD, progressive disease; PFS, progression&#8208;free survival; PR, partial response; OS, overall survival; RECIST, Response Evaluation Criteria In Solid Tumors; SD, Stable disease.</p></fn></table-wrap-foot></table-wrap></sec></body><back><ack id="onco12293-sec-0014"><title>Acknowledgments</title><p>Research funding support was provided by Momenta Pharmaceuticals.</p></ack><fn-group><fn fn-type="other" id="onco12293-note-1201"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01621243">NCT01621243</ext-link></p><p><bold>Sponsor(s)</bold>: Momenta Pharmaceuticals</p><p><bold>Principal Investigator</bold>: Eileen M. O'Reilly</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12293-note-4392"><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p></fn><fn id="onco12293-note-0202"><p>See the related commentary on page <ext-link ext-link-type="doi" xlink:href="10.1634/theoncologist.2017-0453">1424</ext-link>.</p></fn></fn-group><sec id="onco12293-sec-0015" sec-type="disclosure"><title>Disclosures</title><p><bold>Eileen M. O'Reilly:</bold> Celgene, MedImmune, Halozyme (C/A), Celgene, MabVax, Roche, Momenta Pharmaceuticals, Sanofi, Oncomed, MedImmune, AstraZenica, Bristol&#8208;Meyers Squibb (RF); <bold>James Roach:</bold> Momenta Pharmaceuticals (E, OI [former]); <bold>Molly Rosano:</bold> Momenta Pharmaceuticals (E, OI); <bold>Silva Krause:</bold> Momenta Pharmaceuticals (E, OI); <bold>William Avery:</bold> Momenta Pharmaceuticals (E); <bold>Julie Wolf:</bold> Novella Clinical (E); <bold>Keith Flaherty:</bold> Momenta (C/A); <bold>Darrell Nix:</bold> Momenta (C/A). The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12293-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12293-cit-0001">
<string-name><surname>Cosgrove</surname>
<given-names>RH</given-names></string-name>, 
<string-name><surname>Zacharski</surname>
<given-names>LR</given-names></string-name>, 
<string-name><surname>Racine</surname>
<given-names>E</given-names></string-name> et al. <article-title>Improved cancer mortality with low&#8208;molecular&#8208;weight heparin treatment: A review of the evidence</article-title>. <source>Semin Thromb Hemost</source>
<year>2002</year>;<volume>28</volume>:<fpage>79</fpage>&#8211;<lpage>88</lpage>.
</mixed-citation></ref><ref id="onco12293-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12293-cit-0002">
<string-name><surname>Zacharski</surname>
<given-names>LR</given-names></string-name>, 
<string-name><surname>Ornstein</surname>
<given-names>DL</given-names></string-name>, 
<string-name><surname>Mamourian</surname>
<given-names>AC.</given-names></string-name>
<source>Low&#8208;molecular&#8208;weight heparin and cancer. Semin Thromb Hemost</source>
<year>2000</year>;<volume>26</volume>(<issue>suppl 1</issue>):<fpage>69</fpage>&#8211;<lpage>77</lpage>.
<pub-id pub-id-type="pmid">11011810</pub-id></mixed-citation></ref><ref id="onco12293-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12293-cit-0003">
<string-name><surname>Zacharski</surname>
<given-names>LR</given-names></string-name>, 
<string-name><surname>Ornstein</surname>
<given-names>DL.</given-names></string-name>
<article-title>Heparin and cancer</article-title>. <source>Thromb Haemost</source>
<year>1998</year>;<volume>80</volume>:<fpage>10</fpage>&#8211;<lpage>23</lpage>.
<pub-id pub-id-type="pmid">9684778</pub-id></mixed-citation></ref><ref id="onco12293-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12293-cit-0004">
<string-name><surname>Kakkar</surname>
<given-names>AK</given-names></string-name>, 
<string-name><surname>Williamson</surname>
<given-names>RC.</given-names></string-name>
<article-title>Antithrombotic therapy in cancer</article-title>. <source>BMJ</source>
<year>1999</year>;<volume>318</volume>:<fpage>1571</fpage>&#8211;<lpage>1572</lpage>.
<pub-id pub-id-type="pmid">10364099</pub-id></mixed-citation></ref><ref id="onco12293-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12293-cit-0005">
<string-name><surname>Altinbas</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Coskun</surname>
<given-names>HS</given-names></string-name>, 
<string-name><surname>Er</surname>
<given-names>O</given-names></string-name> et al. <article-title>A randomized clinical trial of combination chemotherapy with and without low&#8208;molecular&#8208;weight heparin in small cell lung cancer</article-title>. <source>J Thromb Haemost</source>
<year>2004</year>;<volume>2</volume>:<fpage>1266</fpage>&#8211;<lpage>1271</lpage>.
<pub-id pub-id-type="pmid">15304029</pub-id></mixed-citation></ref><ref id="onco12293-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12293-cit-0006">
<string-name><surname>Klerk</surname>
<given-names>CP</given-names></string-name>, 
<string-name><surname>Smorenburg</surname>
<given-names>SM</given-names></string-name>, 
<string-name><surname>Otten</surname>
<given-names>HM</given-names></string-name> et al. <article-title>The effect of low molecular weight heparin on survival in patients with advanced malignancy</article-title>. <source>J Clin Oncol</source>
<year>2005</year>;<volume>23</volume>:<fpage>2130</fpage>&#8211;<lpage>2135</lpage>.
<pub-id pub-id-type="pmid">15699479</pub-id></mixed-citation></ref><ref id="onco12293-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12293-cit-0007">
<string-name><surname>Icli</surname>
<given-names>F</given-names></string-name>, 
<string-name><surname>Akbulut</surname>
<given-names>H</given-names></string-name>, 
<string-name><surname>Utkan</surname>
<given-names>G</given-names></string-name> et al. <article-title>Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer</article-title>. <source>J Surg Oncol</source>
<year>2007</year>;<volume>95</volume>:<fpage>507</fpage>&#8211;<lpage>512</lpage>.
<pub-id pub-id-type="pmid">17192920</pub-id></mixed-citation></ref><ref id="onco12293-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12293-cit-0008">
<string-name><surname>Lebeau</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Chastang</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Brechot</surname>
<given-names>JM</given-names></string-name> et al. <article-title>Subcutaneous heparin treatment increases survival in small cell lung cancer. &#8220;Petites Cellules&#8221; Group</article-title>. <source>Cancer</source>
<year>1994</year>;<volume>74</volume>:<fpage>38</fpage>&#8211;<lpage>45</lpage>.
<pub-id pub-id-type="pmid">8004580</pub-id></mixed-citation></ref><ref id="onco12293-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12293-cit-0009">
<string-name><surname>von Delius</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Ayvaz</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Wagenpfeil</surname>
<given-names>S</given-names></string-name> et al. <article-title>Effect of low&#8208;molecular&#8208;weight heparin on survival in patients with advanced pancreatic adenocarcinoma</article-title>. <source>Thromb Haemost</source>
<year>2007</year>;<volume>98</volume>:<fpage>434</fpage>&#8211;<lpage>439</lpage>.
<pub-id pub-id-type="pmid">17721628</pub-id></mixed-citation></ref><ref id="onco12293-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12293-cit-0010">
<string-name><surname>Cunningham</surname>
<given-names>MS</given-names></string-name>, 
<string-name><surname>Preston</surname>
<given-names>RJ</given-names></string-name>, 
<string-name><surname>O'Donnell</surname>
<given-names>JS.</given-names></string-name>
<article-title>Does antithrombotic therapy improve survival in cancer patients?</article-title>
<source>Blood Rev</source>
<year>2009</year>;<volume>23</volume>:<fpage>129</fpage>&#8211;<lpage>135</lpage>.
<pub-id pub-id-type="pmid">19046797</pub-id></mixed-citation></ref><ref id="onco12293-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12293-cit-0011">
<string-name><surname>Kuderer</surname>
<given-names>NM</given-names></string-name>, 
<string-name><surname>Ortel</surname>
<given-names>TL</given-names></string-name>, 
<string-name><surname>Francis</surname>
<given-names>CW.</given-names></string-name>
<article-title>Impact of venous thromboembolism and anticoagulation on cancer and cancer survival</article-title>. <source>J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>4902</fpage>&#8211;<lpage>4911</lpage>.
<pub-id pub-id-type="pmid">19738120</pub-id></mixed-citation></ref><ref id="onco12293-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12293-cit-0012">
<string-name><surname>Akl</surname>
<given-names>EA</given-names></string-name>, 
<string-name>
<surname>van Doormaal</surname>
<given-names>FF</given-names></string-name>, 
<string-name><surname>Barba</surname>
<given-names>M</given-names></string-name> et al. <article-title>Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: A Cochrane systematic review</article-title>. <source>J Exp Clin Cancer Res</source>
<year>2008</year>;<volume>27</volume>:<fpage>4</fpage>.
<pub-id pub-id-type="pmid">18577254</pub-id></mixed-citation></ref><ref id="onco12293-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="onco12293-cit-0013">
<string-name><surname>Sanford</surname>
<given-names>D</given-names></string-name>, 
<string-name><surname>Naidu</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Alizadeh</surname>
<given-names>N</given-names></string-name> et al. <article-title>The effect of low molecular weight heparin on survival in cancer patients: An updated systematic review and meta&#8208;analysis of randomized trials</article-title>. <source>J Thromb Haemost</source>
<year>2014</year>;<volume>12</volume>:<fpage>1076</fpage>&#8211;<lpage>1085</lpage>.
<pub-id pub-id-type="pmid">24796727</pub-id></mixed-citation></ref><ref id="onco12293-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="onco12293-cit-0014">
<string-name><surname>Sasisekharan</surname>
<given-names>R</given-names></string-name>, 
<string-name><surname>Shriver</surname>
<given-names>Z</given-names></string-name>, 
<string-name><surname>Venkataraman</surname>
<given-names>G</given-names></string-name> et al. <article-title>Roles of heparan&#8208;sulphate glycosaminoglycans in cancer</article-title>. <source>Nat Rev Cancer</source>
<year>2002</year>;<volume>2</volume>:<fpage>521</fpage>&#8211;<lpage>528</lpage>.
<pub-id pub-id-type="pmid">12094238</pub-id></mixed-citation></ref><ref id="onco12293-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="onco12293-cit-0015">
<string-name><surname>Fuster</surname>
<given-names>MM</given-names></string-name>, 
<string-name><surname>Esko</surname>
<given-names>JD.</given-names></string-name>
<article-title>The sweet and sour of cancer: Glycans as novel therapeutic targets</article-title>. <source>Nat Rev Cancer</source>
<year>2005</year>;<volume>5</volume>:<fpage>526</fpage>&#8211;<lpage>542</lpage>.
<pub-id pub-id-type="pmid">16069816</pub-id></mixed-citation></ref><ref id="onco12293-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="onco12293-cit-0016">
<string-name><surname>Zhou</surname>
<given-names>H</given-names></string-name>, 
<string-name><surname>Roy</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Cochran</surname>
<given-names>E</given-names></string-name> et al. <article-title>M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis</article-title>. <source>PLoS One</source>
<year>2011</year>;<volume>6</volume>:<fpage>e21106</fpage>.
<pub-id pub-id-type="pmid">21698156</pub-id></mixed-citation></ref><ref id="onco12293-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="onco12293-cit-0017">
<string-name><surname>Oosterom</surname>
<given-names>I</given-names></string-name>, 
<string-name><surname>Schultes</surname>
<given-names>BC</given-names></string-name>, 
<string-name><surname>Lockley</surname>
<given-names>M</given-names></string-name> et al. <article-title>Characterization of effects of M402 on EMT in pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Res</source>
<year>2013</year>;<volume>73</volume>:<fpage>302</fpage>.
</mixed-citation></ref><ref id="onco12293-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="onco12293-cit-0018">
<string-name><surname>Von Hoff</surname>
<given-names>DD</given-names></string-name>, 
<string-name><surname>Ervin</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Arena</surname>
<given-names>FP</given-names></string-name> et al. <article-title>Increased survival in pancreatic cancer with nab&#8208;paclitaxel plus gemcitabine</article-title>. <source>N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>1691</fpage>&#8211;<lpage>1703</lpage>.
<pub-id pub-id-type="pmid">24131140</pub-id></mixed-citation></ref></ref-list></back></article>